SUBJECT EXPERT COMMITTEE
GEMCOVAC-19: India's First mRNA COVID-19 Vaccine to Get Emergency Use Authorisation Soon
COVID-19 Vaccine Precaution Dose: Bharat Biotech Seeks DCGI's Permission to Conduct Covaxin Booster Trials in 2-18 Age Group
COVID-19 in India: Bharat Biotech Asked To Provide More Data on 'Covaxin' for Below 12-Year-Olds
COVID-19 Vaccine Update: Subject Expert Panel Recommends Corbevax Vaccine for Children Aged 5-11
India's First Homegrown mRNA-Based COVID-19 Vaccine to Be Tested Amid Omicron Spike: Official Sources
COVID-19 Vaccine Covaxin for 2-18 Years: Centre Examining Expert Committee's Recommendations, Informs Union Health Ministry in Rajya Sabha
Dr Reddy's Denied Approval for Phase 3 Trials of Sputnik Light COVID-19 Vaccine by Govt Panel
COVID-19 Vaccine Update: Govt Asks SII to Submit Trial Results of Adults For Novavax's Coronavirus Vaccine Covavax
Covaxin Phase 3 Trial Data: DCGI’s Expert Panel Says Bharat Biotech’s Vaccine 77.8% Effective
Bharat Biotech’s COVID-19 Vaccine COVAXIN Shows 77.8% Efficacy in Phase III Trials, Say Sources
Sputnik V: Yet To Receive Subject Expert Committee Communication on Russia’s COVID-19 Vaccine Approval, Says Dr Reddy’s Laboratories
COVID-19 Nasal Vaccine: CDSCO Meet on Bharat Biotech’s Coronavirus Vaccine Clinical Trial Underway
Google Trends